Using deep learning and Raman spectroscopy for early cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a deep learning model that utilizes Raman spectroscopy to enhance early cancer screening across multiple types of cancer, including colorectal and gastric cancers. It involves collecting blood samples from healthy individuals and patients with diagnosed cancers or precancerous conditions. The study focuses on evaluating the model's accuracy in identifying cancer-specific features in the spectral data and classifying patients based on their risk. The data undergoes preprocessing to standardize and optimize it for deep learning analysis, allowing for the identification of patterns associated with cancer presence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.
* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.
* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.
* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.

Exclusion Criteria:

* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time
* Post-cancer treatment patients.

Where it's running

• The First Affiliated Hospital to Nanchang University
  Nanchang, Jiangxi, China Recruiting
• The Second Affiliated Hospital to Nanchang University
  Nanchang, Jiangxi, China Recruiting
• Huashan Hospital Affiliated to Fudan University
  Shanghai, Shanghai Municipality, China Recruiting
• The Second Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Jiasheng Xu, MD
• Email: 1821286450@qq.com
• Phone: +86 18720996980

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How the CES1 liver enzyme affects capecitabine levels in people with colorectal, gastric, or esophageal cancer

  This project will see if differences in the CES1 enzyme change how capecitabine is processed and whether that affects side effects like hand‑foot syndrome in adults starting capecitabine with oxaliplatin for colorectal, gastric, or esophageal cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07114627

• AI-assisted non-contrast CT for detecting multiple cancers

  This study is testing whether an AI tool can help find different types of cancer earlier in healthy people getting routine check-ups.

  Recruiting Changhai Hospital · Shanghai, Shanghai Municipality · NCT06632886

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.